Clinical demographics, anti-CD20 therapy dosing, and CD19+ lymphocytes according to treatment response by ADAMTS13 activity
| Clinical feature . | Complete response (n = 149) . | Partial response (n = 22) . | Minimal response (n = 6) . | P . |
|---|---|---|---|---|
| Age at treatment, y | 46.6 | 55.8 | 59.0 | <.001 |
| Gender (male/female), n | 45/104 | 8/14 | 4/2 | .16 |
| Ethnicity, n | .09 | |||
| Caucasian | 50 | 8 | 2 | |
| Black African | 16 | 4 | 4 | |
| Black Caribbean | 36 | 3 | 0 | |
| Asian | 21 | 3 | 0 | |
| Mixed | 2 | 0 | 0 | |
| Other | 6 | 0 | 0 | |
| Unknown | 18 | 4 | 0 | |
| Median no. of rituximab doses | 4 | 4 | 4 | — |
| Median dose of rituximab per cycle (mg) | 500 | 500 | 500 | — |
| Median total dose of rituximab (mg) | 2000 | 1500 | 2000 | — |
| Absolute no. CD19+ lymphocytes (×109/L) | 0.001 | 0.002 | 0 | .05 |
| CD19+ lymphocyte proportion (%) | 0.05 | 0.07 | 0.02 | .33 |
| Clinical feature . | Complete response (n = 149) . | Partial response (n = 22) . | Minimal response (n = 6) . | P . |
|---|---|---|---|---|
| Age at treatment, y | 46.6 | 55.8 | 59.0 | <.001 |
| Gender (male/female), n | 45/104 | 8/14 | 4/2 | .16 |
| Ethnicity, n | .09 | |||
| Caucasian | 50 | 8 | 2 | |
| Black African | 16 | 4 | 4 | |
| Black Caribbean | 36 | 3 | 0 | |
| Asian | 21 | 3 | 0 | |
| Mixed | 2 | 0 | 0 | |
| Other | 6 | 0 | 0 | |
| Unknown | 18 | 4 | 0 | |
| Median no. of rituximab doses | 4 | 4 | 4 | — |
| Median dose of rituximab per cycle (mg) | 500 | 500 | 500 | — |
| Median total dose of rituximab (mg) | 2000 | 1500 | 2000 | — |
| Absolute no. CD19+ lymphocytes (×109/L) | 0.001 | 0.002 | 0 | .05 |
| CD19+ lymphocyte proportion (%) | 0.05 | 0.07 | 0.02 | .33 |